A low prevalence of H pylori and endoscopic findings in HIV-positive Chinese patients with gastrointestinal symptoms

Table 1 Patient data and clinicopathology

	HIV-positive (n = 122) (%)	HIV-negative (n = 29) (%)	P
Age (yr)	40.8 ± 7.9	49.5 ± 12.7	NS
Male	49	15	NS
Female	73	14	NS
Gastrointestinal symptoms			NS
Abdominal pain and distention	38	14	NS
Dyspepsia	42	6	NS
Diarrhea	27	1	0.02
Nausea and vomiting	47	8	NS
Odynophagia and dysphagia	21	0	0.035
Others	16	6	NS
Consumption of medications within one month, n (%)
Antibiotics	47 (38.5)	3 (10.3)	0.004
Proton pump inhibitor	3 (2.5)	4 (13.8)	0.034
H pylori infection	27 (22.1)	13 (44.8)	0.013
Candida esophagitis	19 (15.6)	0 (0)	0.05
Peptic ulcer	5 (4.1)	6 (20.7)	0.007
Chronic atrophy gastritis	30 (24.6)	2 (6.9)	0.036
CMV infection	6 (4.9)	0 (0)	0.49

CMV: Cytomegalovirus; NS: Not significant.

Table 2 H pylori infection and previous use of antibiotics related to CD4⁺ count in HIV-positive patients n (%)

CD4+ count	H pylori infection	P	Antibiotic therapy	P
CD4+≥ 200/μL (n = 65)	19 (29.2)	0.044	19 (29.3)	0.024
CD4+ < 200/μL (n = 57)	8 (14.0)		28 (49.1)
CD4+≥ 100/μL (n = 85)	24 (28.2)	0.014	29 (34.1)	0.13
CD4+ < 100/μL (n = 37)	3 (8.1)		18 (48.6)

Table 3 Relationship of CD4⁺ count to H pylori infection and Endoscopic Findings in HIV-positive patients n (%)

	CD4+≥ 200/μL (n = 65)	CD4+ < 200/μL (n = 57)	P
H pylori infection	19 (29.2)	8 (14)	0.044
Candida esophagitis	4 (6.2)	15 (26.3)	0.002
Peptic ulcer	2 (3.1)	3 (5.3)	0.881
Chronic atrophy gastritis	13 (20)	17 (29.8)	0.209
CMV infection	1 (1.5)	5 (8.8)	0.155

Table 4 Relationship of chronic active gastritis to H pylori infection

	HIV-positive group (n = 122)		HIV-negative group (n = 29)
	H pylori + (n = 27)	H pylori – (n = 95)	H pylori + (n = 13)	H pylori – (n = 16)
Chronic active gastritis, n (%)	8 (29.6)	16 (16.8)	8 (61.5)	1 (6.3)
P	0.140		0.005